GlaxoSmithKline and AIDS drugs in South Africa (A): The fight for lives and profits
The case describes the interactions among pharmaceutical companies, NGOs, and governments in the context of the AIDS epidemic in South Africa. Oxfam singled out GSK as the target for its new campaign, “Cut the Cost.” The goal was to hit where it would hurt the most–GSK’s share price. At the same time other NGOs also went after GSK. For GSK the situation in South Africa was extremely delicate. The ultimate issues were patent and price protection globally. The pharmaceutical companies were afraid that cheap generic drugs could flood the West, undermining the entire pricing structure and their ability to fund new research. Defending the patents and prices seemed essential. Yet, fighting the NGOs could bring negative publicity and, ultimately, be self-defeating. Meanwhile, million of people were dying of AIDS in South Africa.
GlaxoSmithKline, Healthcare, Pharmaceuticals
2001-2004
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
In late 2021, Puneet Chhatwal, CEO of Indian Hotels Company Limited IHCL, found himself grappling with a new challenge beyond the impressive growth numbers the company had achieved since his tenure began in 2017 sustainability. Having led IHCL, t...
When a Saudi consortium led by utilities giant Acwa Power signed $8.3 billion in deals this July to build seven solar and wind projects across the kingdom, it marked more than just another line entry in the country’s growing clean energy portfolio...
As companies move from generative AI (gen AI) pilots to scaled efforts with measurable outcomes, many incumbents struggle to turn ambition into impact. Despite rising adoption, most gen AI initiatives fall short on ROI, highlighting the complexity...
Case reference: IMD-7-2648 ©2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in HBR.org 25 July 2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD Brain Circuits 1 July 2025
Research Information & Knowledge Hub for additional information on IMD publications